Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

1 result

  • Active substance : thrombine humaine
  • Date : du 06/10/2019 au 06/10/2023
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
    • Surgical procedures (1)
    • Plus ...
      • Vascular surgery (1)
  • Diseases and conditions (1)
  • Plus ...
    • Blood and lymphatic diseases (1)
    • Plus ...
      • Blood coagulation and hemostasis disorders (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Date
  • Last five years (1)
Language
  • Français (1)
Active substance
  • thrombine humaine (1)
 More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 1 result

  • VERASEAL (fibrinogène humain 80 UI/mL et thrombine humaine 500 UI/mL)

    Medicine - Posted on 16/3/2021
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
vaCqsedcWAuzBRfn